Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 2;9(5):442.
doi: 10.3390/vaccines9050442.

Differential Antibody Response against Conformational and Linear Epitopes of the L1 Proteins from Human Papillomavirus Types 16/18 Is Observed in Vaccinated Women or with Uterine Cervical Lesions

Adolfo Pedroza-Saavedra  1 , Angelica Nallelhy Rodriguez-Ocampo  2 , Azucena Salazar-Piña  3 , Aislinn Citlali Perez-Morales  1   4 , Lilia Chihu-Amparan  1 , Minerva Maldonado-Gama  1 , Aurelio Cruz-Valdez  5 , Fernando Esquivel-Guadarrama  4 , Lourdes Gutierrez-Xicotencatl  1
Affiliations

Differential Antibody Response against Conformational and Linear Epitopes of the L1 Proteins from Human Papillomavirus Types 16/18 Is Observed in Vaccinated Women or with Uterine Cervical Lesions

Adolfo Pedroza-Saavedra et al. Vaccines (Basel). .

Abstract

Antibodies against the Human Papillomavirus (HPV) L1 protein are associated with past infections and related to the evolution of the disease, whereas antibodies against L1 Virus-Like Particles (VLPs) are used to follow the neutralizing antibody response in vaccinated women. In this study, serum antibodies against conformational (VLPs) and linear epitopes of HPV16/18 L1 protein were assessed to distinguish HPV-vaccinated women from those naturally infected or those with uterine cervical lesions. The VLPs-16/18 were generated in baculovirus, and L1 proteins were obtained from denatured VLPs. Serum antibodies against VLPs and L1 proteins were evaluated by ELISA. The ELISA-VLPs and ELISA-L1 16/18 assays were validated with a vaccinated women group by ROC analysis and the regression analysis to distinguish the different populations of female patients. The anti-VLPs-16/18 and anti-L1-16/18 antibodies effectively detect vaccinated women (AUC = 1.0/0.79, and 0.94/0.84, respectively). The regression analysis showed that anti-VLPs-16/18 and anti-L1-16/18 antibodies were associated with the vaccinated group (OR = 2.11 × 108/16.50 and 536.0/49.2, respectively). However, only the anti-L1-16 antibodies were associated with the high-grade lesions and cervical cancer (CIN3/CC) group (OR = 12.18). In conclusion, our results suggest that anti-VLPs-16/18 antibodies are effective and type-specific to detect HPV-vaccinated women, but anti-L1-16 antibodies better differentiate the CIN3/CC group. However, a larger population study is needed to validate these results.

Keywords: HPV vaccine; L1 protein; VLPs; cervical cancer; human papillomavirus; linear and conformational epitopes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of the data; in the writing of the manuscript; or in the decision to publish the results.

Figures

Figure 1
Figure 1
Antibody response against VLPs and L1 from HPV16 and HPV18. The distributions of the antibody levels (EU/mL) obtained from the VLPs and L1 from HPV16 (A) and HPV18 (B) by ELISA were plotted for each group studied and represented as data scatter boxes. The EUs for all the samples were adjusted for the dilution factor (dil 1:100). NL, no lesion; CIN1-2, cervical intraepithelial neoplasia 1–2; CIN3/CC, cervical cancer; Vacc, vaccinated women. Statistical significance * p < 0.05 and *** p < 0.0001.
See this image and copyright information in PMC

References

    1. Ferlay J., Colombet M., Soerjomataram I., Mathers C., Parkin D.M., Pineros M., Znaor A., Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer. 2019;144:1941–1953. doi: 10.1002/ijc.31937. - DOI - PubMed
    1. zur Hausen H. Papillomaviruses in the causation of human cancers—A brief historical account. Virology. 2009;384:260–265. doi: 10.1016/j.virol.2008.11.046. - DOI - PubMed
    1. Campos-Romero A., Anderson K.S., Longatto-Filho A., Luna-Ruiz Esparza M.A., Moran-Portela D.J., Castro-Menendez J.A., Moreno-Camacho J.L., Calva-Espinosa D.Y., Acosta-Alfaro M.A., Meynard-Mejia F.A., et al. The burden of 14 hr-HPV genotypes in women attending routine cervical cancer screening in 20 states of Mexico: A cross-sectional study. Sci. Rep. 2019;9:10094. doi: 10.1038/s41598-019-46543-8. - DOI - PMC - PubMed
    1. Roldao A., Mellado M.C., Castilho L.R., Carrondo M.J., Alves P.M. Virus-like particles in vaccine development. Expert Rev. Vaccines. 2010;9:1149–1176. doi: 10.1586/erv.10.115. - DOI - PubMed
    1. Lowy D.R., Schiller J.T. Prophylactic human papillomavirus vaccines. J. Clin. Investig. 2006;116:1167–1173. doi: 10.1172/JCI28607. - DOI - PMC - PubMed

LinkOut - more resources